Provided by Tiger Trade Technology Pte. Ltd.

InflaRx N.V.

0.9119
-0.0181-1.95%
Post-market: 0.93300.0211+2.31%19:58 EDT
Volume:254.66K
Turnover:230.37K
Market Cap:65.92M
PE:-1.15
High:0.9595
Open:0.9100
Low:0.8751
Close:0.9300
52wk High:1.94
52wk Low:0.7113
Shares:72.29M
Float Shares:60.04M
Volume Ratio:0.55
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7963
EPS(LYR):-0.7963
ROE:-88.63%
ROA:-45.97%
PB:1.37
PE(LYR):-1.15

Loading ...

InflaRx Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 20

InflaRx price target lowered to $14 from $22 at Guggenheim

TIPRANKS
·
Mar 20

Analysts’ Opinions Are Mixed on These Healthcare Stocks: InflaRx (IFRX) and Kuros Biosciences (OtherCSBTF)

TIPRANKS
·
Mar 20

InflaRx NV reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 19

InflaRx Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $(39.501K) Miss $230.000K Estimate

Benzinga
·
Mar 19

InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year

TIPRANKS
·
Mar 19

InflaRx FY 2025 net loss narrows 9.8% to EUR 45.63 million

Reuters
·
Mar 19

Press Release: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Dow Jones
·
Mar 19

InflaRx N.V. Director Mark Kubler Files Initial Statement of Beneficial Ownership

Reuters
·
Mar 18

InflaRx N.V. director Anthony S. Gibney files initial beneficial ownership statement

Reuters
·
Mar 18

InflaRx N.V. Director Hege Hellstrom Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting

Reuters
·
Mar 18

InflaRx N.V. Chief Scientific Officer Guo Renfeng files initial beneficial ownership statement

Reuters
·
Mar 18

InflaRx N.V. SVP Derval OCarroll Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

InflaRx CEO and Director Niels Riedemann Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

InflaRx NV CFO Thomas Taapken files initial beneficial ownership statement

Reuters
·
Mar 18

InflaRx to present Phase 3 vilobelimab data in pyoderma gangrenosum at AAD annual meeting

Reuters
·
Mar 18

InflaRx NV expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
Mar 17

InflaRx Receives Nasdaq Minimum Bid Price Deficiency Notice

Reuters
·
Mar 14

InflaRx NV to release full-year 2025 results

Reuters
·
Mar 12